Home / 2021 / April / 20

Daily Archives: April 20, 2021

Five-year patient-level meta-analysis of ILLUMENATE EU RCT and Pivotal study results confirms safety profile of Philips Stellarex .035” low-dose Drug-Coated Balloon

April 20, 2021

Stellarex is the only Drug-Coated Balloon (DCB) to consistently demonstrate no difference in mortality every year through five years when compared with percutaneous transluminal angioplasty (PTA), the current standard of care

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the five-year patient-level meta-analysis of two major randomized controlled trials (RCTs). The findings, which represent the highest level of the evidence pyramid [1], confirm the long-term safety of the Philips Stellarex Drug-Coated Balloon (DCB). The meta-analysis shows no difference in mortality at each year through five years for patients treated with the Stellarex low-dose DCB when compared with those treated with percutaneous transluminal angioplasty (PTA), the current standard of care. The meta-analysis was presented at the 2021 Charing Cross International Symposium.

The ILLUMENATE EU RCT and ILLUMENATE Pivotal RCT meta-analysis comprises approximately 600 patients in Europe and the U.S., and is the largest homogenous patient data set of paclitaxel DCB RCTs with five-year follow-up [2,3]. After five years, the meta-analysis for the two studies shows no difference in survival rates, with 80.4% for the Stellarex DCB arm and 80.4% for the PTA arm. The analysis also demonstrates that the use of one or multiple Stellarex DCBs in a patient is not a predictor of mortality. The meta-analysis has a vital status follow-up compliance of over 90%.

“This meta-analysis confirms and reinforces the consistent and durable long-term safety profile of the low-dose Stellarex DCB through five years,” said William Gray, MD, FACC, FSCAI, and President of the Lankenau Heart Institute, an investigator for the Stellarex clinical trials who presented the results. “The results are an important contribution to the long-term safety of paclitaxel-coated devices.”

“Stellarex is the only paclitaxel DCB to consistently demonstrate no difference in mortality every year through five years compared to PTA in multiple RCTs and in a patient-level meta-analysis,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “We are committed to providing healthcare providers with accurate and transparent data to help them make an informed decision on the optimal treatment for each patient with peripheral arterial disease. With its low drug dose and unique drug coating composition, Stellarex is a logical choice for those who require this option.”

Featuring Philips EnduraCoat technology, a unique coating consisting of a polyethylene glycol excipient with amorphous and crystalline paclitaxel particles dispersed in it, Philips Drug-Coated Balloon – Stellarex .035” is unlike any other DCB for the treatment of peripheral artery disease. EnduraCoat technology provides efficient drug transfer and effective drug residency coupled with high coating durability and minimal particulate loss, thereby enabling a low therapeutic drug dose.

Philips’ Image Guided Therapy business provides complete procedural solutions of systems, smart devices, disease-specific software and services for minimally invasive procedures, helping caregivers decide, guide, treat and confirm the right therapy for each patient during their procedure.

[1] https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence.
[2] Katsanos et al. Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. JAHA, December 8, 2018.
[3] Schneider et al. Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials. Catheterization & Cardiovascular Interventions, August 24, 2020.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
E-mail: mark.groves@philips.com

Fabienne van der Feer
Philips Image Guided Therapy
Tel: + 31 622 698 001
E-mail: fabienne.van.der.feer@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


AGC Biologics Expands Partnership with Rocket Pharmaceuticals

Seattle, April 20, 2021 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has expanded its partnership with Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders.

Through the expanded partnership, AGC Biologics will bolster the security of supply of Rocket Pharmaceuticals across their entire lentiviral vector (LVV) pipeline, with the manufacture of LVV. LVV manufacturing will be performed utilizing both the 48L Cell Factory™ Systems and iCellis® 500 bioreactor platforms. All services are currently being performed at AGC Biologics’ state-of-the-art Center of Excellence for Cell and Gene Therapy services in Milan, Italy.

“We are honored that Rocket has placed so much trust with us, as demonstrated by our expanding partnership,” said Mark Womack, AGC Biologics’ Chief Business Officer. “We’re incredibly proud of the Cell and Gene Therapy services and offerings we’ve brought to market to assist our partners in providing life-changing treatments for those living with rare diseases.”

In response to their customer needs and incredible market demand, AGC Biologics has developed a reproducible, high quality and quantity process for the industrial-scale production of LVV. This process allows for the successful scale of LVV manufacture without affecting critical quality attributes (CQA), ultimately improving the commercial viability of LVV-based gene therapies.

About AGC Biologics: 
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to deliver the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our global network spans the U.S., Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 1,600 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

David Self
AGC Biologics


Virtusa Partners with People’s United Bank to Launch New Customer-Decisioning Hub with Virtusa’s vEngage

vEngage Built on Pega Customer Decision Hub and Adobe Experience Platform

SOUTHBOROUGH, Mass., April 20, 2021 (GLOBE NEWSWIRE) — Virtusa Corporation, a global provider of digital strategy, digital engineering, and IT services and solutions today announced that People’s United Bank is leveraging its vEngage solution built on Pega Customer Decision Hub™ and Adobe Experience Platform to power the financial institution’s new customer decisioning hub. People’s United Bank is using the engine to enhance its ability to anticipate customers’ financial needs and deliver personalized services to retail and business customers.

A subsidiary of People’s United Financial, Inc. (NASDAQ: PBCT), People’s United Bank is a diversified financial services company offering commercial and retail banking as well as wealth management services. With more than $63 billion in assets, the bank is committed to meeting the ongoing needs of its customers, which includes anticipating and solving problems. With vEngage, People’s United Bank can access a 360-degree view of each customer’s digital journey and how they are interacting with the business. With this insight, the bank can fully understand each client’s needs and address them at precisely the right time.

“Whether in one of our branches or online, People’s United Bank has long understood the importance of being attentive to our customers across their individual customer journeys,” said James Roy, Senior Vice President Digital Marketing of People’s United Bank. “We are excited about our work with Virtusa, which is helping us expand our client-centric capabilities by designing and deploying a new customer decisioning engine, powered by Pegasystems. By deploying modern decisioning capabilities and automated orchestration that further strengthens our ability to personalize customers’ digital experiences, we can continue to meet the unique needs of each customer as they engage with us through multiple digital channels.”

With digital banking continuing to grow, the ability to personalize at scale has become a competitive differentiator. According to a KPMG study, customers consistently rank banks with great personalization capabilities as best in class. Built on the Pega Customer Decision Hub™ and Adobe Experience Platform, Virtusa’s vEngage helps banks modernize their sales and marketing efforts by providing them with a single source of truth that they can use to anticipate customer needs and then deliver relevant and compelling experiences, wherever they interact with the customer.

“In the age of digital banking, consumers and businesses have unlimited choices. For many, this decision is being based on the institution’s ability to personalize their experiences, and adapt to their needs,” said Sanjay Deshpande, Executive Vice President and Head of Banking and Financial Services, Americas of Virtusa. “We are excited to work with partners including Pegasystems and Adobe to help evolve the bank’s customer commitment as more and more customers engage with them online for critical financial guidance.”

With vEngage banks gain an array of new features such as the opportunity to:

  • Achieve a significant uptick in loyalty platform engagement and redemption rates.
  • Create and manage offers, configure and launch campaigns, segment management and lead creation. With the help of Pega Customer Decision Hub, they can then determine the most profitable customers for each pitch campaign or offer based on the likelihood of a positive response.
  • Once a customer profile is matched with a specific offer, vEngage automates customer outreach through an outbound email system. Using a predictive analytics engine, teams can then refine messaging based on the person’s previous responses to offers and outreach mail.
  • Leverage AI for cognitive processing to deliver a better customer experience with Hyper-personalized, 1-to-1 marketing campaigns.
  • Data-backed recommendations for “Next Best Offer,” “Next Best Communication,” and “Next Best Action.”
  • Expand next-best-action capabilities into new channels (SMS, mobile app, chatbot), cross-channel, dynamic content for personalization, integrate with contact center (Salesforce Service Cloud).

About Virtusa
Virtusa Corporation is a global provider of digital business strategy, digital engineering, and information technology (IT) services and solutions that help clients change, disrupt, and unlock new value through innovation engineering. Virtusa serves Global 2000 companies in the Banking, Financial Services, Insurance, Healthcare, Communications, Media, Entertainment, Travel, Manufacturing, and Technology industries.

Virtusa helps clients grow their business with innovative products and services that create operational efficiency using digital labor, future-proof operational and IT platforms, and rationalization and modernization of IT applications infrastructure. This is achieved through a unique approach blending deep contextual expertise, empowered agile teams, and measurably better engineering to create holistic solutions that drive business forward at unparalleled velocity enabled by a culture of cooperative disruption.

Virtusa is a registered trademark of Virtusa Corporation. All other company and brand names may be trademarks or service marks of their respective holders.

Doug Fraim
Conversion Marketing

Brunswick Exploration Announces Start of 2021 Exploration Campaign

MONTREAL, April 20, 2021 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (“BRW” or the “Company”) is pleased to announce the start of its 2021 exploration programs across its portfolio of projects in Quebec and New Brunswick, Canada.

New Brunswick

  • Fundy Gold (Gold-Silver-Copper): BRW has assembled a field team of experienced prospectors to further investigate the very encouraging gold-in-soil anomalies, including 16,200 ppb Au (see news release dated March 16th) in the Roger’s Lake area. The 2021 prospecting program will cover the entire property over the coming months. BRW is also commencing a five hundred metre spaced regional till survey in May to further refine areas of interest across its entire 53,000 hectares of mineral claims.
  • Bathurst Mining Camp (Zinc-Lead-Copper-Silver): A newly-interpreted lithological model of the prolific Brunswick Belt from Brunswick No.12 to Gilmour South is nearly complete (Figure 1). This interpretation has identified 8 kilometres of unexplored Brunswick Belt along strike from the past-producing Brunswick No.6 mine. BRW will drill test this newly identified extension as well as some coincident Titan 24 geophysical anomalies in H2 2021.


  • Lac Édouard (Nickel-Copper-Cobalt): Drilling is expected to begin in June for a minimum of 3,000 meters to test the mineralized system along strike and down dip of the historical massive sulfide zone. Prospecting has begun across the entire property to follow up on several unexplained nickel geochemical anomalies.
  • Waconichi (Zinc-Copper-Silver VMS): An airborne gravity gradiometry survey has just been completed. The survey will allow BRW to filter out selected airborne electromagnetic targets for drilling in H2 2021.

Mr. Killian Charles, President of BRW, commented: “Following the highly encouraging results from our 2020 field program at Fundy Gold, we are excited to begin rigorous prospecting and a regional till survey throughout our extensive land package. Furthermore, with drilling planned at both Lac Édouard and the Bathurst Mining Camp, we expect the summer months to be very exciting for the Company. BRW intends to spend over $3.5M across its portfolio of assets and is fully financed to complete its 2021 exploration program.”

About Brunswick Exploration

The Company, formerly Komet Resources Inc., is part of the Osisko Group of companies and is a Montreal-based mineral exploration venture listed on the TSX-V under symbol BRW. The Company has sold its former African assets and is now focused on exploration and development of gold and base metal properties in Eastern Canada. Current projects include gold-polymetallic vein systems in Southern New Brunswick (Fundy Gold Project), base metals VMS in the Bathurst Camp in northern New Brunswick and in the Chibougamau region of Quebec (Waconichi), and the new Lac Édouard nickel-copper project in Québec.

Investor Relations/information

Mr. Killian Charles, President (info@BRWexplo.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Corporation’s public documents filed on SEDAR at www.sedar.com. Although the Corporation believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Philips produces one hundred millionth blade for its OneBlade, the product that disrupted the grooming market

April 20, 2021

  • Since its launch in 2016, the Philips OneBlade has disrupted grooming markets worldwide, creating a new category a single tool for shaving, trimming and edging
  • OneBlade Face + Body adds the ability to trim, style and edge facial and body hair even in the most intimate areas
  • One hundred million blades is an important milestone Philips’ global innovation teams will keep expanding the OneBlade range and engaging new audiences

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the production of its one hundred millionth OneBlade blade. This impressive milestone is testament to the success of the collaborative effort put in by Philips’ grooming innovation team in the Netherlands, who teamed up with other Philips innovation teams around the globe to produce the advanced OneBlade shaving and grooming tool, sharing their expertise and experience. The team keeps on innovating and disrupting the grooming market with new OneBlade solutions, such as the OneBlade Face + Body, and will keep on pushing the boundaries by expanding the ranges and engaging new audiences. The Philips OneBlade subscription-model makes the grooming routine as easy and convenient as possible; new blades get delivered to people’s doorstep.

“At Philips, we believe people should be able to embrace their individuality so they can be what they want to be, not just today but next year and the year after,” said Dominique Oh, Business Leader Grooming and Beauty at Philips. “It’s why our innovation teams continue to develop tools that allow them to achieve the look they want in an easy way or find the look that’s right for them. I am proud to see this unique blade, designed and invented by Philips for OneBlade, reaching the important milestone of 100 million blades produced.”

The must-have styling tool of a new generation
Over the last few years, there has been a major shift in facial hair styles that has completely disrupted the grooming market. People worldwide, especially millennials (18 – 34 year olds), are shaving less, styling more, and expressing their individualism by styling their facial hair. Despite this widespread change in behavior, which had not previously been seen for decades, the tools at their disposal had hardly changed until Philips disrupted the shaving and grooming market in 2016 with a new solution – the OneBlade. This unique single tool allows users to style, trim and edge any length of facial hair in complete comfort and convenience. The OneBlade already boasts over 27 million users worldwide, with the number still growing fast.

Continued innovation in premium grooming and beauty
In addition to working on OneBlade innovations, Philips brings other innovations to the personal care market, such as the premium, highly advanced and successful Philips Lumea IPL 9000 series hair removal device for home use, and its new series 9000 electric shavers with SkinIQ technology for those who are looking for a close shave while maintaining healthy looking skin. Today, Philips keeps reinventing the premium space, delivering smart propositions that provide personalized plans and guidance, and stepping into new business models.

For further information, please contact
Laura Seikritt
Philips Global Press Office
Tel: +31 6 20740318
E-mail: Laura.Seikritt@philips.com

Marije Ansing
Philips Global Press Office
Tel: +31 6 50589016
E-mail: Marije.Ansing@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


Matriculation students compounded for not wearing masks can still appeal – Perak Exco Man

— There was no element of unfair treatment against six students of the Perak Matriculation College in Gopeng who were compounded RM1,500 each by the Ministry of Health (MOH) for not wearing face masks yesterday.

State Health, Science, Environment and Green Technology Committee chairman Mohd Akmal Kamarudin said the MOH officers issuing the compound were only carrying out their duties to ensure standard operating procedures (SOPs) were complied with to check the spread of COVID-19.

He said the students could still make an appeal to reduce the compounds and the state government was confident the students would be able to settle them.

‘’I am confident the compounds will be reduced to the minimum and affordable to the students. God willing, I can also help to resolve it if they cannot afford to pay the compounds,’’ he said.

Mohd Akmal was speaking to reporters after launching a state-level food safety operation in conjunction with Ramadan at the Dataran Taman Orkid Ramadan Bazaar today.

He was asked to comment on the incident which went viral on social media and received various criticism from netizens who questioned the action of the MOH as the students had been staying at the college for the past five months and not allowed to go out.

The MOH personnel were said to have issued compounds of RM1,500 each to several students who did not wear face masks or placed them under their chins.

In the meantime, Mohd Akmal urged all parties to respect the duties of the enforcement agencies who have been working tirelessly since last year to contain the COVID-19 pandemic.

‘’I urge all quarters to stay calm. This matter can be solved especially now in the month of Ramadan. View MOH in a positive light as it is working hard so that we can return to a normal life,’’ he said.

Health director-general Tan Sri Dr Noor Hisham Abdullah, through his Twitter account late last night, said the Perak Health Department was investigating the matter, adding that appropriate action would be taken.

Source: BERNAMA News Agency

COVID: IPT students not allowed to leave campus – Uggah

— Students of higher educational institutions (IPT) are not allowed to leave campus or return home following the increase in COVID-19 infection in the community, said Deputy Chief Minister Datuk Amar Douglas Uggah Embas today.

Uggah, who is also State Disaster Management Committee (JPBM) chairman, said other than IPT students, the directive is also applicable to students of residential schools, who have to stay put in their respective hostels for their safety and their families.

‘’On seeing schools in red zones in Sarawak closed until May 3, we have made the decision that the directive involving IPT and residential school students too be enforced for 14 days,’’ he told a media conference here, today.

Meanwhile, Uggah said JPBN had decided to end the Enhanced Movement Control Order (EMCO) in Kampung Batu Gong, Siburan because the second screening did not find any new positive cases.

‘’In addition, there is no evidence to show infection is still taking place in the area and JPBM wishes to take this opportunity to thank all agencies and villagers for their co-operation in making the EMCO successful,’’ he said.

A total of 600 new COVID-19 cases were detected in Sarawak today resulting in an increase in the total number to 25,129 cases.

Meanwhile, State Education director, Dr Chin Zin Hing said the vaccination process at the Sibu Indoor Stadium had to be postponed as the supply of vaccines has not received the clearance of the Health Ministry (MOH).

The State Health Department’s initial plan was to vaccinate 800 frontliners and the National COVID-19 Immunisation Programme second phase recipients on today’s waiting list.

‘’However, we were informed on April 16 there was a problem of ‘lot release’ by MOH and the vaccines could not be supplied to Sibu,” he said in the same media conference.

Source: BERNAMA News Agency